Matt Cannon

By Matt Cannon

News Editor

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


The recall of thousands of ramen noodles cases, issued after a labeling error, has been given the U.S. Food and Drug Administration's (FDA) second highest risk warning: a Class II.

Kobayashi Noodle USA recalled 3,745 cases of its Raw Ramen Noodle on August 5 after package labels failed to identify soy as the source of lecithin, the FDA said.

The recall was listed as a Class II event, the middle of three possible hazard classifications, by the FDA on Monday. The products were distributed in California, the agency said.

Read More on News

Newsweek contacted Kobayashi Noodle USA for comment outside of regular office hours on Thursday.

Ramen, with noodles beef and egg

...

Why It Matters

The FDA classifies this recall as Class II, which the agency describes as a situation "in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."

The presence of an undeclared major allergen on a food label can put people with allergies at risk. U.S. law requires the identification of nine major food allergens on product labeling: milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, soybeans, and sesame.

What To Know

What People Are Saying

Food safety expert Darin Detwiler, adviser to the Alliance for Recall Ready Communities, told NTD: "Such recalls are often triggered by supplier notifications or routine product testing, with common causes being reports of allergic reactions or the discovery of undeclared allergens upon reviewing ingredient lists."

FDA inspectors carry out a hazard assessment before issuing one of three risk levels. The three classifications are:

What Happens Next

The recall remains ongoing.

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines